Slides
Page 1
Growing Together Investor Presentation August 2026 Cover Optiono/s new photo
Page 2
Forward-looking Statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws (“forward-looking statements” or “forward-looking information”). Statements other than statements of historical fact contained in this presentation may be forward-looking statements, including, without limitation, management’s expectations, intentions and beliefs concerning anticipated future events, results, circumstances, economic performance or expectations with respect to Extendicare Inc. (the “Company” or “Extendicare”), including, without limitation: statements regarding dividend levels, its business operations, business strategy, growth strategy, results of operations and financial condition, including anticipated timelines and costs in respect of development projects; statements relating to the acquisition of CBI Home Health LP and CBI (GP) 3 Inc. and their respective subsidiaries (collectively, “CBI Home Health”), from CBI Health LP and CBI GP Holdco Inc., including the anticipated benefits of the acquisition, the integration and anticipated post-closing acquisition synergies and the timing of those synergies; statements relating to the acquisition of Closing the Gap Healthcare Group Inc. and certain affiliates (collectively, “Closing the Gap; statements relating to the agreements entered into with Axium LTC Limited Partnership and its affiliates (“collectively, Axium”) and two limited partnership joint ventures with Axium in respect of the acquisition, disposition, ownership, operation and redevelopment of LTC homes in Ontario and Manitoba; and statements relating to expected future current income taxes and maintenance capex impacting AFFO. Forward-looking statements can often be identified by the expressions “anticipate”, “believe”, “estimate”, “expect”, “intend”, “objective”, “plan”, “project”, “will”, “may”, “should” or other similar expressions or the negative thereof. These forward- looking statements reflect the Company’s current expectations regarding future results, performance or achievements and are based upon information currently available to the Company and on assumptions that the Company believes are reasonable. Actual results and developments may differ materially from results and developments discussed in the forward-looking statements, as they are subject to a number of risks and uncertainties. Although forward-looking statements are based upon estimates and assumptions that the Company believes are reasonable based upon information currently available, these statements are not representations or guarantees of future results, performance or achievements of the Company and are inherently subject to significant business, economic and competitive uncertainties and contingencies and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Extendicare to differ materially from those expressed or implied in the statements. For further information on the risks, uncertainties and assumptions that could cause Extendicare’s actual results to differ from current expectations, refer to “Risks and Uncertainties” and “Forward-looking Statements” in Extendicare’s Q2 2026 Management’s Discussion and Analysis “MD&A” and latest Annual Information Form filed by Extendicare with the securities regulatory authorities, available at www.sedarplus.ca and on Extendicare’s website at www.extendicare.com. Readers should not place undue reliance on such forward-looking statements and assumptions as management cannot provide assurance that actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. The forward- looking statements speak only as of the date of this presentation. Except as required by applicable securities laws, the Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Non-GAAP Measures This presentation makes reference to certain non-International Financial Reporting Standards (“IFRS”) measures (“Non-GAAP”), Non-GAAP ratios and supplementary financial measures to evaluate the performance of the Company. The terms “EBITDA”, “Adjusted EBITDA”, “net operating income” (“NOI”), “adjusted NOI”, “home health care adjusted NOI”, “LTC adjusted NOI”, “managed services NOI”, and “adjusted funds from operations” (“AFFO”), including any related per share amounts, are Non- GAAP financial measures; the term “Adjusted EBITDA margin”, “NOI margin”, “home health care NOI margin”, “LTC NOI margin”, “managed services NOI margin”, “payout ratio”, “interest coverage ratio”, “debt to Adjusted EBITDA” and “pro forma debt to Adjusted EBITDA” are Non-GAAP ratios; and “debt to GBV” is a supplementary financial measure, all of which do not have any standardized meaning prescribed within IFRS and therefore may not be comparable to similar measures presented by other companies. Investors are cautioned that such measures should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. Management believes that the Non-GAAP financial measures provide a more consistent basis to compare the performance of the Company between the periods and improve comparability between other companies. They provide additional information to readers of this presentation to enhance their understanding of the Company’s financial performance. These measures are also used by the Company to set financial targets for its management incentive plans and to monitor the Company’s compliance with its debt covenants. For further information regarding these Non- GAAP measures and applicable reconciliations, please refer to “Non-GAAP Measures”, “Funds From Operations and Adjusted Funds From Operations” and “Select Quarterly Financial Information” of our management’s discussion and analysis for the fiscal years ended December 31, 2025 and December 31, 2024 and for the quarter ended June 30, 2026, each of which are available on Extendicare’s profile on SEDAR+ at www.sedarplus.ca and on Extendicare’s website at www.extendicare.com, which are incorporated by reference in this presentation. 2 Cautionary statement
Page 3
Extendicare (TSX: EXE) Canada’s largest seniors’ care provider focused on long-term care and home health care • Strong growth opportunities: Organic growth driven by demographic trends augmented by deep acquisition pipeline in a fragmented Canadian market • Industry leading performance: Technology platform in the cloud enables high quality, efficient service delivery and acquisition synergies • Strong balance sheet: Low leverage and free cash flow support acquisitions and shareholder returns • Capital efficient: Joint venture with Axium Infrastructure enables long-term care growth with minimal capital requirements • Revenue stability: Over 90% of revenue is derived from government contracts that insulate results from the economic cycle 3 1968 $208M available liquidity(1) ~2.5x debt to adjusted EBITDA (1)(2) $0.5292 annual dividend/share ~37% payout ratio(3) 58 years of providing seniors’ care (1) Figures as at June 30, 2026 (2) “Adjusted EBITDA” is a Non-GAAP financial measure and “payout ratio” is a Non-GAAP ratio. See “Cautionary Statement – Non-GAAP Financial Measures” in this presentation for a definition of this measure and certain related information (3) Payout ratio based on trailing twelve months (“TTM”) ended June 30, 2026, adjusted to exclude out-of-period items as outlined on slide 16
Page 4
45.7% 41.2% Services-focused growth Business model enables growth without significant capital requirements 4 Direct care for seniors Home health care hours (4)~27M Home health care 58 Long-term care homes owned Long-term care Managed services 39 Homes under contract Management & consulting Third-party & JV beds served 162K Group purchasing NOI contribution by segment(1) Geographically diversified operations(2) Province ON AB MB BC QC Other Total Home health care hours delivered (TTM 000’s) 15,326 1,429 256 10 - 892 17,913 LTC homes owned – beds 38 5,410 14 1,514 6 973 - - - - - - 58 7,897 Assist and JV beds under management contract(3) 5,188 - 810 - - - 5,998 SGP 3rd party & JV beds served 59,630 20,473 2,140 31,806 38,402 9,203 161,654 High growth business model to expand home health care services and build new LTC homes through capital efficient JV with Axium to generate managed services revenue Positioned for GROWTH TTM Q2 2026 Adjusted NOI(1) $275.5M Home health care $125.9M Managed services $36.1M 13.1% (1) TTM Q2 2026 adjusted NOI excludes out-of-period items, refer to slide 16 for details and the impact; “NOI” is a Non-GAAP financial measures. See “Cautionary Statement – Non-GAAP Financial Measures” in this presentation for a definition of this measure and certain related information (2) Figures as at June 30, 2026 (3) Represents 39 homes, including 29 operational LTC homes owned in the joint ventures with Axium in which the Company has a 15% managed interest (4) Estimated annualized volume based on TTM volumes ending June 30, 2026 of 17.9M plus pro forma adjustment for CBI Home Health of ~9.0M Long-term care $113.5M
Page 5
2x 3x Meeting the needs of a growing demographic Compelling growth in long-term care and home health care Canadian population aged 85+ Building new LTC homes to address the rising demand for long-term care • Seniors aged 85+ increasing at ~4% per year(1) • LTC waitlist of ~50,000(2) in Ontario(2) • Need >200,000 new LTC beds in Canada by 2035(3) Enhancing home health services to ease health care system strain • ParaMed currently provides ~27M hours of home health care services annually • Home care volume growth outpacing seniors’ population growth to bridge LTC shortfall (1) Source: Statistics Canada, Table 17-10-0057-01, Projected population as of July 1, 2025, released January 2026 (2) Source: Ontario Ministry of Long-Term Care Client Profile Database (“CPRO”), March 2026 (3) The Conference Board of Canada; Sizing Up the Challenge; Meeting the Demand for Long-Term Care, November 2017 0.86 1.61 2.70 0.0 0.5 1.0 1.5 2.0 2.5 3.0 2006 2011 2016 2021 2026 2031 2036 2041 2046 2051 Observed Projected (millions) 5
Page 6
Ontario LTC beds per 1,000 people aged 75+ Development activity has not kept up with growing demand; home health care bridges the gap (1) Source: Financial Accountability Office of Ontario, April 2025, Nov 2025 (2) Beds in Operation = Licensed Beds – Closed 3rd and 4th Ward Beds (3) Source: OLTCA Home Profile Data, Nov 2025 (4) Source: Ontario Ministry of Long-Term Care Client Profile Database (“CPRO”), March 2026 Ontario LTC beds per 1,000 people over 75• From 1996 to 2006, over 23,000 LTC beds were added in Ontario, raising the ratio to a high of 99 beds per 1,000 Ontarians aged 75+ • From 2006 to 2024, only 4,200 LTC beds were added, despite a growing seniors’ population • The ratio has fallen to 57 beds per 1,000, with ~50,000 people (4) on the LTC waitlist • To maintain the current ratio, Ontario must add 4,000 beds annually as the aged 75+ population grows Licensed beds per 1,000(1) Beds in operation per 1,000(2) Closed 3rd and 4th ward beds(3) 93 99 94 92 90 88 93 94 94 99 96 94 92 90 90 88 86 84 82 81 79 77 74 72 67 64 62 60 57 0 10 20 30 40 50 60 70 80 90 100 1996-97 1997-98 1998-99 1999-00 2000-01 2001-02 2002-03 2003-04 2004-05 2005-06 2006-07 2007-08 2008-09 2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 2017-18 2018-19 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 LTC beds per 1,000 Ontarians aged 75+ 6
Page 7
CBI Home Health acquisition CBI Adjusted EBITDA $69.6M for FY2025 ~12.4% ahead of announcement pro forma • $570 million acquisition of CBI Home Health closed April 1, 2026, making ParaMed the leading home health care platform in Canada • Advances services focused strategy and highly complementary to ParaMed, with substantial presence in Western Canada and opportunities for significant synergies • CBI FY2025 Adjusted EBITDA was $69.6M, up ~12.4% from $61.9M pro forma when we announced the transaction • CBI Q2 2026 Adjusted EBITDA was $18.5M • Q2 2026 ADV of 33,609 reflects organic growth in CBI comparable to ParaMed (1) CBI Home Health results on a standalone basis for the year ended December 31, 2025, adjusted for estimated IFRS 16 lease accounting adjustments of $5.5M, net of Extendicare Quality of Earnings (“QoE”) EBITDA adjustments of $3.3M and excludes approximately $15.0M in out of period adjustments for retroactive funding and workers compensation rebates related to prior periods. (further details can be found on Extendicare’s press release issued on May 12, 2026 and the Business Acquisition Report (“BAR Report”) filed on SEDAR+ at www.sedarplus.com) $504M Revenue(1) (FY 2025) $69.6M Adjusted EBITDA(1) (FY2025) ~12M hours Annual Volume (Annualized Q2 2026 ADV 33,609) ~8.5k Team Members 7
Page 8
Home health care Strong volume and NOI growth supported by investments in training and recruiting programs and technology; highly fragmented market offers M&A opportunities 8 • Robust demand for home health care services driven by aging Canadian population, strained hospital system, limited supply of LTC homes and strong preference to age at home • Margin growth as technology-enabled back-office drives scalable, efficient service delivery • Ontario government is making significant investments in home health care; additional $2.2 billion announced in Fall 2025/Spring 2026 to expand home care capacity; timing of rate increases can vary causing short-term margin impacts, but historically, rate increases have kept pace with labour cost increases 9.9 11.0 13.0 17.9 5M 10M 15M 20M 2023 2024 2025 TTM Q2-26 Home Health Care Hours of Service 9.4% 11.4% 12.8% 13.3% 0% 2% 4% 6% 8% 10% 12% 14% 0 $20M $40M $60M $80M $100M $120M $140M 2023 2024 2025 TTM Q2-26 Home Health Care Adjusted NOI & NOI Margin(1)(2) (1) “NOI” and “adjusted NOI” are Non-GAAP financial measures and “home health care NOI margin” is a Non-GAAP ratio. See “Cautionary Statement – Non-GAAP Financial Measures” in this presentation for a definition of this measure and certain related information (2) Adjusted NOI & NOI margins exclude items outlined on slide 16 99% of ParaMed revenue from provincial government contracts Volume growth TTM Q2 2026 +80.6% from 2023 (26.7% CAGR) Adjusted NOI margin(2) TTM Q2 2026 at multi- year high of ~13.3%
Page 9
Long-term care Industry-leading scale and strong operating performance drive stable NOI growth • LTC segment has returned to pre-pandemic occupancy and NOI • Extendicare operates 58 fully owned LTC homes • Provincial funding model enables stable operating margins • Annual rate increases mitigate the impact of inflation and support more hours of care 9 8.4% 10.4% 10.9% 11.8% 0% 2% 4% 6% 8% 10% 12% 0 $20M $40M $60M $80M $100M $120M 2023 2024 2025 TTM Q2-26 LTC Adjusted NOI & NOI Margin(1)(2) 97.4% 97.9% 98.1% 98.3% 80% 85% 90% 95% 100% 2023 2024 2025 TTM Q2-26 LTC Average Occupancy (1) “NOI” and “adjusted NOI” are Non-GAAP financial measures and “long-term care NOI margin” is a Non-GAAP ratio. See “Cautionary Statement – Non-GAAP Financial Measures” in this presentation for a definition of this measure and certain related information (2) Adjusted NOI & NOI margins exclude items as outlined on slide 16 58 fully owned LTC homes with 7,897 beds Average occupancy consistently above the 97% needed to receive full funding Adjusted NOI margin(2) TTM Q2 2026 at 11.8% +90 bps from 2025
Page 10
Building for the future Continued progress on redevelopment program: opened 320-bed home in Ottawa and sold 320-bed Sudbury project into the Axium JV in Q2 10 (1) Represents operational Class C beds to be replaced, excluding 38 ward-style beds that are no longer in service in the Class C bed home (2) Development costs are defined on an IFRS basis (which includes the cost of land, hard construction and soft development costs, furniture, fixtures and equipment, financing costs and capitalized interest costs during construction), net of any capital development government grant receivable on substantial completion of construction, if applicable Upgrading our portfolio quality, driving management fee growth Six LTC homes (1,408 new beds) under construction in Axium JV to replace 1,072 Class C beds Opened Extendicare Beauclaire (320-beds, Ottawa) in May 2026; Extendicare Forest Trail (256-beds, Peterborough) on track to open in Q3 2026 Target breaking ground on one project in Q4 2026 (256-beds, Ottawa) Pipeline of 17 projects representing more than ~3,700 beds replacing ~1,900 Class C beds in various stages of planning Redevelopment funded via capital-efficient JV model Sold the vacated West End Villa Class C home for $12.1M in February 2026 Sold 320-bed Sudbury project into the Axium JV for $18.1M (net of 15% retained interest) in May 2026 Redevelopment projects # of beds # Class C beds replaced(1) Expected opening Estimated development costs(2) ($ millions) Forest Trail (Peterborough) 256 172 Q3-26 106.0 Garneau Park (Orleans) 256 234 Q1-27 103.3 St. Catharines 256 136 Q1-27 106.4 Port Stanley 128 44 Q1-27 52.7 London 192 170 Q2-27 77.7 Sudbury 320 278 Q1-29 125.9 1,408 1,034 572.0 Forest TrailBeauclaire
Page 11
Managed services | Extendicare Assist and SGP Growth in SGP purchasing clients and new homes opened in the Axium JV drive NOI growth • Highest margin segment, focused on expanding service offerings and geographic reach • Extendicare’s managed services segment has two offerings: • Extendicare Assist: provides management, consulting and other services to third parties and its joint venture homes, enabling clients to provide high-quality, cost-efficient services in a complex regulatory environment • SGP Purchasing Network: Offers access to cost-effective products and services to other seniors’ care providers • Substantially insulated from inflation with minimal capital needs 11 52.5% 53.5% 55.0% 56.3% 0% 10% 20% 30% 40% 50% 60% 70% 0 $15M $30M $45M 2023 2024 2025 TTM Q2-26 Managed Services NOI and NOI Margin 9,783 9,909 6,237 5,998 2023 2024 2025 TTM Q2-26 Assist Management Contract Beds (at period end) (1,2) 136,164 146,292 153,575 161,654 2023 2024 2025 TTM Q2-26 SGP Purchasing Network Beds (at period end, 3rd party & JV)(2) (1) Assist management contracts declined in Q2 2025 largely due to Revera’s sale of 21 Class C homes to a third party on May 1, 2025 and 9 Class C homes to Extendicare on June 1, 2025, resulting in the termination of management agreements with Extendicare Assist (2) Includes 29 operational homes (4,206 beds) in the joint venture with Axium in which Extendicare owns a 15% managed interest SGP 3rd party & JV clients ~161,700 beds +11.9% CAGR since Q2 2023 Operate 39 LTC homes, with 5,998 beds(2) Consistent 50-55% NOI margins(3)
Page 12
Senior unsecured credit structure established in Q2 Weighted average interest rate down 80bps and average maturity increased to 5.1 years Senior unsecured credit structure and mortgage prepayments completed in Q2 2026 add capital allocation flexibility through lower borrowing costs, improved maturity profile and lower mandatory repayments (1) Pro forma Consolidated Debt as at March 31, 2026, includes $153.7M drawn on the prior existing senior secured revolver and $154.5M of additional borrowing under the Senior Secured Delayed Draw Term Loan incurred to fund the CBI Home Health acquisition that closed on April 1, 2026. Consolidated Debt As at June 30, 2026 Pro Forma Consolidated Debt As at March 31, 2026 ('000s, unless otherwise noted) Interest Rate Year of Maturity June 30, 2026 Interest Rate Year of Maturity Pro Forma March 31, 2026 CMHC mortgages, fixed rate 2.65% - 3.35% 2026 - 2032 $ 18,692 2.65% -7.70% 2026-2037 $ 32,867 Non-CMHC mortgages and loans 5.56% - 5.64% 2038 $ 46,206 5.05% - 5.64% 2027-2038 $ 89,496 Lease liabilities 4.27% - 5.50% 2026 - 2033 $ 32,723 4.27% - 5.50% 2026-2033 $ 16,141 Senior Unsecured Notes (BBB stable) 4.35% 2031 $ 450,000 - - $ - Senior Unsecured Revolver 4.27% 2029 $ 103,700 - - $ - Senior Secured Revolver - - $ - 5.15% 2027 $ 153,700 CMHC mortgages, variable rate - - $ - Variable 2027 $ 18,860 Senior Secured Delayed Draw Term Loan - - $ - 5.30% 2027 $ 327,688 Total debt, before deferred financing costs $ 651,321 $ 638,752 Weighted average interest rate 4.4% 5.2% Weighted average term to maturity (years) 5.1 2.9 12
Page 13
Strong liquidity and credit metrics Favourable maturity profile and pro forma Debt to Adjusted EBITDA of ~2.5x post-CBI acquisition with ~$208M of available liquidity 13 • Improved maturity profile with unsecured revolving facility maturity extended to April 2029 and 5-year $450M senior unsecured notes maturing in April 2031 (BBB stable) • Pro forma Debt to Adjusted EBITDA(4) is estimated to be ~2.5x(4), reflecting a full-year pro forma impact of the CBI Acquisition • BBB stable rating from Morningstar DBRS Debt maturities as at June 30, 2026(2) ($ millions) Established Unsecured Senior Credit structure in Q2 2026, reducing borrowing costs and improving maturity outlook 7.9 2.5 4.5 4.7 5.0 5.2 5.4 29.7 4.0 7.5 5.7 4.3 3.4 2.5 5.3 103.7 2026 2027 2028 2029 2030 2031 Thereafter Mortgage/loan principal at maturity Mortgage amortization Lease liabilities Unsecured Revolving Facility Senior Unsecured Notes (2031) (3) “Interest coverage ratio” , “debt to Adjusted EBITDA” and “pro forma debt to Adjusted EBITDA are Non -GAAP ratios, and “debt to GBV” is a supplementary financial measure. See “Cautionary Statement – Non-GAAP Financial Measures” in this presentation for a definition of this measure and certain related information (1) Debt includes current portion of long-term debt and letters of credit drawn on the revolving credit facility; excludes deferred financing costs (2) Debt maturities exclude letters of credit drawn on the revolving credit facility As at June 30, 2026 Cash Available Revolving Facility Long-term debt(1) Weighted Average Rate $93M $115M $683M ~4.4% 450.0 2.6x 4.2x 7.9x 10.0x 9.3x 7.4x 4.0x 2.3x 2.1x 2.5x 38.6% 37.0% 31.4% 26.0% 35.3% 2022 2023 2024 2025 Pro forma TTM Q2-26 Debt Metrics(1)(3)(4) TTM interest coverage Debt/Adjusted EBITDA Debt/GBV (4) Pro forma TTM Q2-26 debt metrics are calculated using estimated pro forma Adjusted EBITDA of $273.6M and interest expense of $29.3M. Pro forma Adjusted EBITDA of $273.6M is derived from Extendicare’s Adjusted EBITDA of $221.4M for the TTM Q2-26, plus $52.2M representing nine months of CBI Home Health’s standalone Adjusted EBITDA of $69.6M for the year ended December 31, 2025. Pro forma interest expense of $29.3M is derived from the Company’s 4.4% weighted average interest rate of long -term debt outstanding as at June 30, 2026. Further details on CBI Home Health’s standalone Adjusted EBITDA can be found in the Company’s Business Acquisition Report on Form 51-102F4 and associated press release issued on May 12, 2026, as filed on SEDAR+ at www.sedarplus.com and on Extendicare’s website at www.extendicare.com
Page 14
Appendix o/s new photos Q4-25 deck
Page 15
15 Identify Project Pipeline of 17 projects representing more than 3,500 beds replacing ~1,600 C beds Develop Project Acquire land, design and tender project, secure permits & MLTC approval to construct Sell Project to JV Sell project to JV, with reimbursement to Extendicare of upfront land, project planning and construction costs incurred prior to sale, and opportunity for gains on sale and development Manage Operations Extendicare earns management fees for the term of the 30-year government license + 15% share of JV earnings Recycle Capital Sell vacated Class C home, recycling capital into redevelopment and 15% interest in the JV for new projects JV acquires project 85% Axium/15% Extendicare JV assumes construction contract & project financing (backstopped by Axium & Extendicare guarantees) Development fees paid to Extendicare to manage construction and commissioning of the new home JV owns the new home and pays recurring management fees to Extendicare Distributes excess cashflow to JV unitholders Distributions on 15% JV interest Extendicare Joint Venture Manage Construction & Commissioning Extendicare earns development fees during construction Management Fees Development Fees Funds LTC redevelopment and expansion, driving revenue growth in Managed Services Joint Venture with Axium Infrastructure
Page 16
Adjustments to revenue, NOI, EBITDA and AFFO Years ended December 31, 2023, 2024, and 2025, and twelve months ended June 30, 2026 • 2023 results impacted by COVID-19 related funding and costs and other out- of-period items o Home health care recognized $1.0M of COVID-19 related funding and costs o LTC recognized COVID-19 related funding and costs of $27.7M and $15.6M, respectively, for a net $12.1M impact to NOI o LTC recognized out-of-period funding of $6.6M • 2024 results impacted by out-of-period funding and costs o Home health care recognized $13.6M of retroactive funding and offsetting one -time costs in Q1 2024 in connection with the 6.7% rate increase announced in Q4 2023 o LTC recognized out-of-period funding of $15.3M • 2025 results impacted by out-of-period funding and costs, and workers’ comp. rebates o Home health care recognized $11.0M of retroactive funding and offsetting one -time costs in Q1 2025 in connection with the 4.0% rate increase announced in Q4 2024 o LTC recognized $2.3M of out-of-period funding offset by $2.3M of retroactive union wage adjustments o Workers’ comp. rebates recognized in home health care of $9.4M and LTC of $5.6M • TTM Q2 2026 results impacted by out-of-period funding and costs, and workers’ comp. rebates o Home health care recognized $0.6M of retroactive funding and offsetting costs of $0.3M, for a net impact of $0.3M o LTC recognized $5.0M of out-of-period funding, offset by $2.3M of retroactive union wage adjustments, for a net impact of $2.7M o Workers’ comp. rebates recognized in home health care of $5.5M and LTC of $2.9M o AFFO further impacted by settlement of DSUs of $6.4M (after -tax impact of $8.7M payroll withholding tax) or $0.066 AFFO/share 16 (1) “Adjusted EBITDA items” are net of tax (@ 26.5%) and include the 15% pro rated share of out-of-period adjustments related to the Axium JVs ($1.0M 2024, $0.5M 2025 and $0.7M TTM Q2 2026) (2) TTM Q2 2026 AFFO/basic share computed using YTD Q2 2026 weighted average shares of 95.5M Impact of out-of-period items on Revenue, NOI, Adjusted EBITDA, Net Earnings, FFO and AFFO FY FY FY TTM Q2 Impact on: 2023 2024 2025 2026 Revenue $35.3M $28.9M $13.3M $5.6M Home health care $1.0M $13.6M $11.0M $0.6M Long-term care $34.3M $15.3M $2.3M $5.0M NOI and Adjusted EBITDA $18.7M $15.3M $15.0M $11.4M Home health care ‒ ‒ $9.4M $5.8M Long-term care $18.7M $15.3M $5.6M $5.6M Net earnings $13.7M $15.7M $14.8M $8.6M Adjusted EBITDA items(1) $13.7M $12.3M $11.5M $9.0M Other income ‒ $4.0M $3.7M $4.8M Fair value adjustments $(0.1)M $(0.5)M $(0.5)M $0.7M Interest and costs on early repayment of long-term debt ‒ ‒ ‒ $(6.0)M EPS (basic)(2) $0.161 $0.187 $0.173 $0.090 FFO Adjusted EBITDA items(1) $13.7M $12.3M $11.5M $9.0M FFO/basic share(2) $0.161 $0.146 $0.135 $0.094 AFFO Adjusted EBITDA items(1) $13.7M $12.3M $11.5M $9.0M Settlement of DSUs ‒ ‒ ‒ $(6.4)M AFFO/basic share(2) $0.161 $0.146 $0.135 $0.027
Page 17
Financial Summary Years ended December 31, 2023, 2024, and 2025, and twelve months ended June 30, 2026 17 (1) TTM Q2 2026 basic and diluted share amounts computed using YTD Q2 2026 weighted average shares of 95.5M and 96.7M, respectively Select Annual and TTM Q2-26 Information FY 2023 margin FY 2024 margin FY 2025 margin TTM Q2 2026 margin Revenue $1,305.0M $1,466.2M $1,660.4M $1,978.6M Home health care $469.1M $566.0M $701.1M $950.0M Long-term care $788.1M $827.4M $892.1M $964.4M Managed services $47.8M $72.7M $67.2M $64.2M NOI $151.0M 11.6% $201.5M 13.7% $236.8M 14.3% $286.8M 14.5% Home health care $44.2M 9.4% $62.8M 11.1% $97.5M 13.9% $131.6M 13.9% Long-term care $81.8M 10.4% $99.8M 12.1% $102.4M 11.5% $119.1M 12.4% Managed services $25.1M 52.5% $38.9M 53.5% $36.9M 55.0% $36.1M 56.3% Adjusted EBITDA $95.2M 7.3% $144.5M 9.9% $175.6M 10.6% $221.4M 11.2% Net earnings $34.0M $75.2M $96.7M $121.3M EPS (basic)(1) $0.400 $0.893 $1.132 $1.270 EPS (diluted)(1) $0.400 $0.859 $1.113 $1.255 FFO $56.2M $95.3M $113.7M $152.2M FFO/basic share(1) $0.661 $1.132 $1.332 $1.594 FFO/diluted share(1) $0.647 $1.062 $1.309 $1.574 AFFO $61.0M $92.8M $103.7M $128.3M AFFO/basic share(1) $0.720 $1.102 $1.214 $1.343 AFFO/diluted share(1) $0.681 $1.017 $1.194 $1.327